|1.||Schönthal, Axel H: 13 articles (12/2012 - 05/2005)|
|2.||Petasis, Nicos A: 10 articles (12/2012 - 05/2005)|
|3.||Lu, Yan-Hua: 8 articles (12/2014 - 11/2004)|
|4.||Chen, Thomas C: 8 articles (12/2012 - 05/2005)|
|5.||Hofman, Florence M: 8 articles (12/2012 - 05/2005)|
|6.||Kardosh, Adel: 8 articles (03/2010 - 05/2005)|
|7.||El Ghouzzi, Vincent: 6 articles (05/2015 - 02/2003)|
|8.||Bargonetti, Jill: 5 articles (01/2015 - 10/2002)|
|9.||Louie, Stan G: 5 articles (12/2012 - 04/2007)|
|10.||Gaffney, Kevin J: 5 articles (12/2012 - 01/2008)|
12/01/2007 - "DCPC is an efficient treatment for refractory glaucoma. "
01/01/2015 - "Our study confirmed that transscleral DCPC is a useful, effective and safe procedure with predictable amount of IOP decrease, which makes it the treatment of choice for refractory glaucoma."
09/01/2011 - "Both DCPC and CCT proved to be safe and effective IOP-lowering methods in patients with refractory glaucoma. "
09/01/2011 - "In a prospective, randomized, controlled clinical study, 40 eyes of 40 patients with refractory glaucoma were randomly assigned in 2 groups of 20 eyes each to receive either DCPC or CCT. "
09/01/2011 - "The aim of the present study was to evaluate the efficacy of diode laser cyclophotocoagulation (DCPC) and cyclocryotherapy (CCT) in the treatment of refractory glaucoma and compare the postoperative complications and discomfort rates. "
12/01/2015 - "A recent randomised trial (SMaRT, Symptom Management Research Trials, Oncology-2) found that a collaborative care treatment programme (Depression Care for People with Cancer, DCPC) was highly effective in treating depression in patients with cancer. "
06/01/2014 - "One hundred thirty-nine patients were entered and treated up to the point of early study termination due to concerns by the data-monitoring committee (DMC) that Ca/Mg adversely affected tumor response. "
03/01/2010 - "Most studies on DMC, however, focused on its effects on tumor cells. "
09/01/2009 - ""Depression Care for People with Cancer" (DCPC) has been designed to be integrated into specialist cancer services and is being evaluated in the Symptom Management Research Trials (SMaRT) Oncology series of randomized controlled trials. "
06/15/2007 - "In this study, we have compared molecular targets associated with signaling pathways activated by DMC and MC in several human cancer cell lines. "
01/01/2013 - "The analgesic effects of CXBs on pain behaviors, especially those of DMC, suggest that activation of Kv7/M K(+) channels may play an important role in the analgesic action of CXB. "
01/01/2013 - "We compared the effects of CXB and its two structural analogues, unmethylated CXB (UMC) and 2,5-dimethyl-CXB (DMC), on Kv7/M currents and pain behavior in animal models. "
02/01/2010 - "Considering the correlation of topical cartilaginous surface DMC and subchondral density patterns, clinical application of CT-OAM seems to be recommendable in the case of undefined middle foot pain."
01/01/2002 - "This study explored a phenomenon labeled Diffuse Muscle Coactivation (DMC) as a possible source of pain in fibromyalgia. "
01/01/2002 - "Diffuse muscular coactivation (DMC) as a potential source of pain in fibromyalgia -- part 1."
06/01/2014 - "The aim of this study is to answer the question: does a dual mobility cup (DMC) decrease the dislocation risk? "
12/01/2015 - "We conducted a retrospective study in this population so as to: (1) assess whether cemented fixation of a DMC without a reinforcement device leads to a higher loosening rate, (2) confirm its efficacy in preventing dislocations in subjects at high risk of instability, and (3) measure the functional results. "
09/01/2015 - "Use of a DMC in revision THA was associated with a slightly higher dislocation rate (1/72, 1.4%) than in primary THA, whereas 5-year survival was comparable. "
12/01/2014 - "In order to know outcomes at two years, we prospectively followed a continuous series of 78 patients to demonstrate that cementless dual-mobility cup (DMC) used in revision THA is safe as regards dislocation risk and bone fixation. "
06/01/2014 - "The goal was reached for the patients of group 2 who had more risks factors for dislocation (age, aetiology, American Society of Anesthesiologists and Devane scores) than those of group 1. When using a DMC, we observed a low rate of dislocation in primary THA (0.9 %). "
|5.||Body Weight (Weight, Body)
12/28/2011 - "DMC was administered intraperitoneally (ip) (5, 10, or 20 mg/kg of body weight) for 7 days prior to the administration of CCl(4) (0.1%, ip). "
05/01/2010 - "Although previous studies failed to significantly decrease the risk of DMC by the intensive therapy for hyperglycemia presumably due to the marked increases in severe hypoglycemic events and body weight, the patients in the intensive therapy group in J-DOIT3 have shown well-controlled blood glucose as well as BP and LDL with a very few severe hypoglycemic episodes. "
12/01/2013 - "Pretreatment with polymeric N-isopropyl acryl amide (PNIPAM) nanoparticles formulation of all three curcuminoids (curcumin (Cur), demethoxycurcumin (DMC), and bisdemethoxycurcumin (BDMC)) at doses (100 μg/kg body weight) given intranasally was effective in bringing significant changes on all the parameters. "
04/01/1994 - "Male Sprague-Dawley rats were given single ip doses of corn oil (control), coumarin (0.86 and 1.71 mmol/kg body weight), 3,4-dimethylcoumarin (3,4-DMC, 1.71 and 2.57 mmol/kg), 3-, 4- and 6-methylcoumarins (3-MC, 4-MC and 6-MC, 1.71 mmol/kg) and 3- and 4-methyloctahydrocoumarins (3-MOHC and 4-MOHC, 2.57 mmol/kg) and hepatotoxicity assessed after 24 hr. Coumarin administration produced dose-related hepatic necrosis and a marked elevation of plasma alanine aminotransferase and aspartate aminotransferase activities. "
|6.||glucuronyl glucosamine glycan sulfate (Vessel)
|7.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|8.||Prostaglandins E (PGE)
|2.||Low-Level Laser Therapy (LLLT)
|3.||Length of Stay
|5.||Heterologous Transplantation (Xenotransplantation)